| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President R&D
3 companies
Dolsten Mikael serves as a President R&D at PFE and has filed Form 4s across 3 companies. Across recent SEC filings that breaks down to 0 buys and 16 sells. Those positions are worth an estimated $9.4M at current prices.
Historically, Dolsten Mikael's trades have earned a middling insider score of 56/100 across 3 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +12.1%.
The biggest single holding is PFE (~$8.7M) as President R&D. The recent filings there lean toward selling, a net 123,566 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | A Agilent Technologies, Inc. | Director | Sell | 634 | $151.38 | $95,971.75 | -11.4% | - | - | |
| May 29, 2026 | A Agilent Technologies, Inc. | Director | Sell | 1,600 | $135.42 | $216,672.00 | -22.4% | +16.4% | - | |
| Dec 1, 2025 | A Agilent Technologies, Inc. | Director | Sell | 2,600 | $149.81 | $389,511.20 | -34.3% | -21.3% | - | |
| May 11, 2022 | PFE Pfizer Inc | President R&D | Sell | 63,902 | $49.32 | $3,151,547.14 | -16.1% | +2.3% | -22.1% | |
| Nov 11, 2021 | PFE Pfizer Inc | President R&D | Sale+OE | 59,664 | $50.29 | $3,000,646.92 | -17.6% | +3.4% | -2.1% |